COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,190 Articles (22,713 medRxiv, 8,477 bioRxiv)

Most recent first Page 1: Articles 1-10  | Next

Large scale prospective evaluation of co-folding across 557 Mac1-ligand complexes and three virtual screens
Kim, J., Correy, G. J., Hall, B. W., Rachman, M. M., Mailhot, O., Togo, T., Gonciarz, R. L., Jaishankar, P., Neitz, R. J., Hantz, E. R., Doruk, Y. U., Stevens, M. G. V., Diolaiti, M. E., Reid, R., Gopalkrishnan, S., Krogan, N. J., Renslo, A. R., Ashworth, A., Shoichet, B. K., Fraser, J. S.
10.64898/2025.12.25.696505 — Posted: 2025-12-28
Combinational adjuvants delivered by ink-jet potentiate naked mRNA vaccines for robust protection against infectious diseases
Qiao, N., Ishikawa, J., Yasui, F., Sano, K., Miyakawa, K., Hayashi, A., Amiry, A. F., Haonan, L., Xueyang, Z., Sato, T., Pasqualini, R., Arap, W., Kataoka, K., Hasegawa, H., Kohara, M., Uchida, S.
10.64898/2025.12.24.696305 — Posted: 2025-12-26
Structural Divergence without Functional Impact: Comparative Characterization of SARS-CoV-2 3CL-Mpro Variants Using Cleavage Site Substrates
Saha, D., Dakhili, S. Y. T., Mar, E., Chen, Y. S., VanPetegem, F., Bromme, D.
10.64898/2025.12.23.696280 — Posted: 2025-12-26
Identification of allo- or orthosteric VHH/single-domain antibodies that enhance or block pathogen binding to Siglec-1 on dendritic cells
Brink, H. J., Affandi, A. J., Man, S., Dekker, N. C. C. T., Grosse Wichtrup, E. A., Bouma, R. G., Seyed Toutounchi, N., Konijn, V. A. L., Stolwijk, J. G. C., van Hamme, J. L., Olesek, K., Heijnen, D. A. M., Fish, A., Moutsiopoulou, A., Celie, P., Dekkers, G., Heukers, R., Mastrobattista, E., Smit, M. J., van Kooyk, Y., Heikema, A. P., Kootstra, N. A., Geijtenbeek, T. B. H., den Haan, J. M. M.
10.64898/2025.12.19.695420 — Posted: 2025-12-22
AI Identifies Broadly Neutralizing Antibodies from an IGHV1-69 Public Antibody Class Exerting Continued Selection Over SARS-CoV-2
Niu, C., Huang, X., Yan, Q., Liu, B., Gao, X., Song, Y., Wang, J., Wang, L., Li, Z., Zheng, H., He, P., Huang, X., Yuan, H., Zou, B., Yang, Y., Wu, F., Yao, Y., Habib, G., Chen, X., Chen, L., He, J., Yao, J., Zhao, J., Xiong, X.
10.64898/2025.12.19.695307 — Posted: 2025-12-22
Infection of 5xFAD mice with a mouse-adapted SARS-CoV-2 does not alter Alzheimer's disease neuropathology yet induces wide-spread changes in gene expression across diverse cell types
Furman, S., Zayou, L., Tsourmas, K. I. I., Javonillo, D. I., Olivarria, G. M., Cheng, Y., Pachow, C., Fernandez, K., Le, L., Edwards, R. A., Nicholas, D., Sanchez, G. P., Baric, R. S., Green, K. N., Lane, T. E.
10.64898/2025.12.19.695600 — Posted: 2025-12-22
An Oral Combination therapy against SARS-CoV-2 based on Synergistic Action of Auranofin and Remdesivir.
Khatun, O., Narayan, R., Nagaraj, S. K., Shiraz, R., Kaliappan, A., Kaur, S., Singh, A., Narayanan, S., Shandil, R., Tomar, S., Tripathi, S.
10.64898/2025.12.19.695342 — Posted: 2025-12-19
The pharmacokinetics, bio-distribution and therapeutic efficacy of a trimeric nanobody against SARS-CoV-2 in the Syrian golden hamster COVID-19 model
Sharma, P., Mega, D., Kirby, A., Buckle, I., Kipar, A., Clark, J., Bentley, E., Eyssen, L., Kijak, E., Herriott, J., Sharp, J., Carroll, M. W., Owens, R., Stewart, J. P.
10.64898/2025.12.17.694727 — Posted: 2025-12-19
IGHV3-53 antibody abundance drives divergent SARS-CoV-2 immune imprinting
Niu, X., Jian, F., Li, Y., Li, K., Lei, S., Song, W., Kong, R., Cai, X., An, R., Wang, Y., Huang, Y., Yu, L., Wang, W., Sun, H., Yu, Y., Wang, J., Zhang, B., Zhu, T., Huang, J., Shao, F., Luo, S., Tan, X., Cao, Y.
10.64898/2025.12.18.694353 — Posted: 2025-12-19
Single-Particle Tracking and Positional Phenotyping Reveals Variant-Specific Early Checkpoints in SARS-CoV-2 Cell Entry
Schulz, F. H., Dreisler, M. W., Koylyu, D., Valero, J., Malle, M. G., Civit, L., Kjems, J., Hatzakis, N. S.
10.64898/2025.12.18.695048 — Posted: 2025-12-19

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).